Who
Richard H. Scheller
Director
Company insider
Files Form 4 as: Director, Alector; Director, Maze Therapeutics; Director, 23andMe Holding Co; Director, DICE Therapeutics; Chairman of R&D, BridgeBio Pharma; Director, Oric Pharmaceuticals; Director, Xenon Pharmaceuticals; EVP-Research, Genentech.
In numbers
- Trades disclosed
- 1,008
- Buys
- 1
- Sells
- 49
- Bought
- $20K
- Sold
- $41.3M
- Companies
- 8
- Companies where not an officer
- 6
- First trade
- 13 Jan 2006
- Last trade
- 17 Jun 2026
- Last filed
- 17 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Jun 2026filed 17 Jun 2026 | ALEC AlectorBiotechnology | SEC FORM 4 Code A | —28,700 at $0.00 | filing |
| 17 Jun 2026filed 17 Jun 2026 | ALEC Alectoroption or derivative · Biotechnology | SEC FORM 4 Code A | —9,450 at $0.00 | filing |
| 17 Jun 2026filed 17 Jun 2026 | ALEC Alectoroption or derivative · Biotechnology | SEC FORM 4 Code A | —9,450 at $0.00 | filing |
| 17 Jun 2026filed 17 Jun 2026 | ALEC AlectorBiotechnology | SEC FORM 4 Code A | —28,700 at $0.00 | filing |
| 8 Jun 2026filed 10 Jun 2026 | MAZE Maze Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,000 at $0.00 | filing |
| 8 Jun 2026filed 10 Jun 2026 | MAZE Maze Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,000 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | ALEC AlectorBiotechnology | SEC FORM 4 Code A | —10,833 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | ALEC AlectorBiotechnology | SEC FORM 4 Code A | —10,833 at $0.00 | filing |
| 22 Sep 2025filed 24 Sep 2025 | MAZE Maze Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,000 at $0.00 | filing |
| 15 Sep 2025filed 16 Sep 2025 | MAZE Maze TherapeuticsBiotechnology | SEC FORM 4 Sold | $464K20,744 at $22.37 | filing |
| 11 Jun 2025filed 12 Jun 2025 | ALEC Alectoroption or derivative · Biotechnology | SEC FORM 4 Code A | —9,450 at $0.00 | filing |
| 11 Jun 2025filed 12 Jun 2025 | ALEC AlectorBiotechnology | SEC FORM 4 Code A | —28,700 at $0.00 | filing |
| 2 May 2025filed 2 May 2025 | ALEC AlectorBiotechnology | SEC FORM 4 Code A | —15,833 at $0.00 | filing |
| 26 Aug 2024filed 28 Aug 2024 | 23andMe Holding Co | SEC FORM 4 Code A | —658,485 at $0.00 | filing |
| 22 Aug 2024filed 23 Aug 2024 | ALEC AlectorBiotechnology | SEC FORM 4 Sold | $228K44,250 at $5.16 | filing |
| 2 Aug 2024filed 10 Oct 2024 | ALEC AlectorBiotechnology | SEC FORM 4 Code A | —15,833 at $0.00 | filing |
| 12 Jun 2024filed 12 Jun 2024 | ALEC AlectorBiotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 6 Sep 2023filed 8 Sep 2023 | 23andMe Holding Co | SEC FORM 4 Code A | —165,088 at $0.00 | filing |
| 9 Aug 2023filed 9 Aug 2023 | DICE Therapeuticsoption or derivative | SEC FORM 4 Code D | —4,357 | filing |
| 9 Aug 2023filed 9 Aug 2023 | DICE Therapeuticsoption or derivative | SEC FORM 4 Code D | —9,138 | filing |
The newest 500 lines are listed; the numbers count every line.
News
ORIC Pharmaceuticals Plans Phase 3 Trial For Enozertinib After Promising Lung Cancer DataORIC · rttnews.com · 23 Oct 2026Oric Pharmaceuticals (NASDAQ:ORIC) CFO Dominic Piscitelli Sells 14,000 Shares of Company StockORIC · themarketsdaily.com · 22 Oct 2026Maze Therapeutics (NASDAQ:MAZE) Stock Rated "Buy" in New Coverage at Canaccord Genuity GroupMAZE · themarketsdaily.com · 20 Oct 2026BridgeBio Pharma (NASDAQ:BBIO) Given New $91.00 Price Target at CitigroupBBIO · dailypolitical.com · 19 Oct 2026Contrasting Xenon Pharmaceuticals (NASDAQ:XENE) and United Therapeutics (NASDAQ:UTHR)XENE · dailypolitical.com · 18 Oct 2026Head to Head Survey: Maze Therapeutics (NASDAQ:MAZE) vs. Cytokinetics (NASDAQ:CYTK)MAZE · dailypolitical.com · 18 Oct 2026Alector (NASDAQ: ALEC) prices shares at a 7.3% premium in stock saleALEC · dailypolitical.com · 18 Oct 2026Alector Announces Pricing of Underwritten OfferingALEC · manilatimes.net · 16 Oct 2026
0 headlines in the last 90 days name Richard H. Scheller; 11 articles from the last 14 days about the 5 companies they traded most, at most three about any one of them.